CAR T-cell Therapy
CAR T-Cell Therapy for Pediatric Cancer
Recruiting1 awardPhase 1
Memphis, Tennessee
This trial is for patients ā¤ 21 years old with relapsed/refractory B7-H3+ solid tumors, investigating the use of autologous T cells genetically engineered to express B7-H3-CARs. The study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.
CAR T-cell Therapy
CAR T Cell Therapy for Pediatric Cancer
Recruiting1 awardPhase 1
Seattle, Washington
This trial tests a new treatment for children and young adults with hard-to-treat solid tumors. It uses the patient's own immune cells, modified to better attack cancer cells. The study aims to see if this approach is safe and effective. This type of therapy has shown remarkable results in young patients with certain types of blood cancers.
ATR Kinase Inhibitor
Olaparib + Ceralasertib for Recurrent Osteosarcoma
Recruiting2 awardsPhase 2
Boston, Massachusetts
This trial is being done to see if using these two drugs together can help patients with osteosarcoma who haven't responded to other treatments, or whose cancer has returned after treatment.
Popular Filters
Trials for Bone Cancer Patients
CAR T-cell Therapy
CAR T Cell Therapy for Pediatric Solid Cancers
Recruiting1 awardPhase 1
Seattle, Washington
This trial is testing genetically-modified T cells to treat solid tumors in children and young adults. The goal is to evaluate safety and feasibility, and to determine if the cells can kill tumors.
Anti-metabolites
nab-Paclitaxel + Gemcitabine for Sarcoma
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is testing if the combination of nab-paclitaxel and gemcitabine can stop tumors from growing in patients whose cancer has come back or did not respond to previous treatments. The study also checks if this combination is safe and tolerable. Nab-paclitaxel (Abraxane) is an albumin-bound paclitaxel that has shown clinical activity in advanced breast and lung cancer and has been tested in combination with gemcitabine for advanced pancreatic cancer, improving response rates and survival.
Trials for Rhabdomyosarcoma Patients
CAR T-cell Therapy
CAR T Cell Therapy for Pediatric Solid Cancers
Recruiting1 awardPhase 1
Seattle, Washington
This trial is testing genetically-modified T cells to treat solid tumors in children and young adults. The goal is to evaluate safety and feasibility, and to determine if the cells can kill tumors.
Anti-metabolites
nab-Paclitaxel + Gemcitabine for Sarcoma
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is testing if the combination of nab-paclitaxel and gemcitabine can stop tumors from growing in patients whose cancer has come back or did not respond to previous treatments. The study also checks if this combination is safe and tolerable. Nab-paclitaxel (Abraxane) is an albumin-bound paclitaxel that has shown clinical activity in advanced breast and lung cancer and has been tested in combination with gemcitabine for advanced pancreatic cancer, improving response rates and survival.
Procedure
DW-MRI for Sarcoma in Young Patients
Recruiting1 award
Memphis, Tennessee
This trial is testing whether a method that doesn't involve radiation (DW-MRI) can be used instead of current methods (CT, nuclear bone scan, PET-CT) to measure how well children with sarcomas are responding to therapy, in order to reduce exposure to harmful effects of ionizing radiation.
Trials for Metastatic Patients
CAR T-cell Therapy
CAR T-Cell Therapy for Neuroblastoma and Osteosarcoma
Recruiting1 awardPhase 1
Chapel Hill, North Carolina
This trial is testing a new cancer treatment that combines two existing ways of fighting disease: antibodies and T cells. Antibodies are molecules that fight infections and protect your body from diseases caused by bacteria and toxic substances. T cells are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. The new treatment being researched is called autologous T lymphocyte chimeric antigen receptor cells (CAR) cells targeted against the disialoganglioside (GD2) antigen that express Interleukin (IL)-15, and the inducible caspase 9 safety switch (iC9
Anti-metabolites
nab-Paclitaxel + Gemcitabine for Sarcoma
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is testing if the combination of nab-paclitaxel and gemcitabine can stop tumors from growing in patients whose cancer has come back or did not respond to previous treatments. The study also checks if this combination is safe and tolerable. Nab-paclitaxel (Abraxane) is an albumin-bound paclitaxel that has shown clinical activity in advanced breast and lung cancer and has been tested in combination with gemcitabine for advanced pancreatic cancer, improving response rates and survival.
Trials With No Placebo
CAR T-cell Therapy
CAR T-Cell Therapy for Neuroblastoma and Osteosarcoma
Recruiting1 awardPhase 1
Chapel Hill, North Carolina
This trial is testing a new cancer treatment that combines two existing ways of fighting disease: antibodies and T cells. Antibodies are molecules that fight infections and protect your body from diseases caused by bacteria and toxic substances. T cells are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. The new treatment being researched is called autologous T lymphocyte chimeric antigen receptor cells (CAR) cells targeted against the disialoganglioside (GD2) antigen that express Interleukin (IL)-15, and the inducible caspase 9 safety switch (iC9
CAR T-cell Therapy
CAR T Cell Therapy for Pediatric Solid Cancers
Recruiting1 awardPhase 1
Seattle, Washington
This trial is testing genetically-modified T cells to treat solid tumors in children and young adults. The goal is to evaluate safety and feasibility, and to determine if the cells can kill tumors.
Anti-metabolites
nab-Paclitaxel + Gemcitabine for Sarcoma
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is testing if the combination of nab-paclitaxel and gemcitabine can stop tumors from growing in patients whose cancer has come back or did not respond to previous treatments. The study also checks if this combination is safe and tolerable. Nab-paclitaxel (Abraxane) is an albumin-bound paclitaxel that has shown clinical activity in advanced breast and lung cancer and has been tested in combination with gemcitabine for advanced pancreatic cancer, improving response rates and survival.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' ā so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back ā in general, verified trials respond to patients within a few days.